InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,181.60
(
-0.43%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
0.00%
)
Bitcoin
60,942.39
(
1.05%
)
Post# of 252426
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

NP1986

Send PM Follow Ignore
Followers 6
Posts 541
Boards Moderated 0
Alias Born 06/07/2011

NP1986

Re: DewDiligence post# 180012

Wednesday, 07/02/2014 11:43:12 PM

Wednesday, July 02, 2014 11:43:12 PM

Post# of 252426
A few days ago, @andybiotech tweeted this little tidbit about the recent IRAK-4 license agreement with LGND from the 8-K:

https://twitter.com/AndyBiotech/statuses/482655058170224640

Additionally, Opus Point Partners, LLC, who identified the opportunity and advised the Company on the transaction, will also be entitled to receive a 1% royalty for annual sales of up to $1 billion.



So if I understand this correctly, the CEO of TG Therapeutics is a partner in Opus Point Partners, who "advised" TG Therapeutics on the deal...and for that he gets a part of the 1% royalty. Wow.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up